VistaGen Therapeutics Inc. [NASDAQ: VTGN] stock went on an upward path that rose over 20.39% on Thursday, amounting to a one-week price increase of more than 23.38%. The company report on February 12, 2021 that VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021.
Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD).
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Strengthened Balance Sheet upon closing of $100 million underwritten public offering.
Over the last 12 months, VTGN stock rose by 261.36%. The average equity rating for VTGN stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $356.15 million, with 81.09 million shares outstanding and 56.54 million shares in the current float. Compared to the average trading volume of 2.97M shares, VTGN stock reached a trading volume of 33786747 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on VistaGen Therapeutics Inc. [VTGN]:
Jefferies have made an estimate for VistaGen Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 18, 2021. The new note on the price target was released on January 04, 2021, representing the official price target for VistaGen Therapeutics Inc. stock. Previously, the target price had yet another raise to $6, while Maxim Group analysts kept a Buy rating on VTGN stock. On February 08, 2018, analysts decreased their price target for VTGN shares from 30 to 22.
The Average True Range (ATR) for VistaGen Therapeutics Inc. is set at 0.25, with the Price to Sales ratio for VTGN stock in the period of the last 12 months amounting to 1187.18. The Price to Book ratio for the last quarter was 2.14, with the Price to Cash per share for the same quarter was set at 0.73.
VTGN Stock Performance Analysis:
VistaGen Therapeutics Inc. [VTGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 23.38. With this latest performance, VTGN shares gained by 5.98% in over the last four-week period, additionally plugging by 255.45% over the last 6 months – not to mention a rise of 261.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTGN stock in for the last two-week period is set at 65.59, with the RSI for the last a single of trading hit 70.72, and the three-weeks RSI is set at 64.06 for VistaGen Therapeutics Inc. [VTGN]. The present Moving Average for the last 50 days of trading for this stock 1.80, while it was recorded at 2.08 for the last single week of trading, and 0.94 for the last 200 days.
Insight into VistaGen Therapeutics Inc. Fundamentals:
Return on Total Capital for VTGN is now -725.79, given the latest momentum, and Return on Invested Capital for the company is -819.37. Return on Equity for this stock declined to -3,087.23, with Return on Assets sitting at -210.01.
Reflecting on the efficiency of the workforce at the company, VistaGen Therapeutics Inc. [VTGN] managed to generate an average of -$2,308,222 per employee.VistaGen Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 35.20 and a Current Ratio set at 35.20.
VTGN Stock EPS
With the latest financial reports released by the company, VistaGen Therapeutics Inc. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VTGN.
VistaGen Therapeutics Inc. [VTGN] Insider Position Details
There are presently around $167 million, or 21.00% of VTGN stock, in the hands of institutional investors. The top three institutional holders of VTGN stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 9,360,000, which is approximately New of the company’s market cap and around 0.10% of the total institutional ownership; VR ADVISER, LLC, holding 9,360,000 shares of the stock with an approximate value of $23.21 million in VTGN stocks shares; and ACUTA CAPITAL PARTNERS, LLC, currently with $18.6 million in VTGN stock with ownership of nearly New of the company’s market capitalization.
Positions in VistaGen Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 35 institutional holders increased their position in VistaGen Therapeutics Inc. [NASDAQ:VTGN] by around 64,187,486 shares. Additionally, 9 investors decreased positions by around 289,739 shares, while 11 investors held positions by with 2,806,411 shares. The mentioned changes placed institutional holdings at 67,283,636 shares, according to the latest SEC report filing. VTGN stock had 28 new institutional investments in for a total of 61,904,065 shares, while 4 institutional investors sold positions of 189,466 shares during the same period.